TIL Therapy Shows Promise in Heavily Pretreated Metastatic Head and Neck Cancer: Phase 2 Trial Results
TIL therapy stabilized disease in 64% of metastatic head/neck cancer patients, extending survival to 9.5 months in heavily treated cases.




We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
These cookies are needed for adding comments on this website.
Google Tag Manager simplifies the management of marketing tags on your website without code changes.